Answers are grounded in this paper and cite their sources.
Palivizumab is cost-effective compared to no prophylaxis in the United Kingdom in many of the subgroups considered, showing that palivizumab would be a cost-effective use of National Health Service resources.
No takes yet. Share an insight, caveat, or question.
Bentley et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: